Toggle Health Problems and D

5,000 U daily raised Vitamin D a bit and helped COVID-19 a bit – RCT June 2021

Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial

Nutrients 2021, 13(7), 2170; https://doi.org/10.3390/nu13072170
by Shaun Sabico 1OrcID,Mushira A. Enani 2,Eman Sheshah 3,Naji J. Aljohani 1,4,Dara A. Aldisi 5,Naif H. Alotaibi 6,Naemah Alshingetti 7,Suliman Y. Alomar 8OrcID,Abdullah M. Alnaami 1,Osama E. Amer 1OrcID,Syed D. Hussain 1 and Nasser M. Al-Daghri 1,*OrcID

5,000 IU statistically reduced only 2 of 11 mild symptoms
Note: Ageusia is associated with loss of taste

P Values


Vitamin D 21 ng ==> 25 ng

COVID-19 treated by Vitamin D - studies, reports, videos

5 most-recently changed Virus entries

Note: >70% of the RCT using Vitamin D to fight COVID-19 were using at least 100,000 IU during the first week
RCTs for COVID-19

The founder of VitaminDWiki had predicted very little success in RCTs using less

Note: Clincal trials in hospitals using much higher doses of Vitamin D have found far better results

Also: Those people who had been taking a good amount of vitamin D before COVID were
1) Less likely to get infected
2) Less likely to need to go to hospital
3) Less likely to have severe COVID-19
4) Less likely to die of COVID-19

Items in both categories Virus and Intervention:

 Download the PDF from VitaminDWiki

Objective: Vitamin D deficiency has been associated with an increased risk of COVID-19 severity. This multi-center randomized clinical trial aims to determine the effects of 5000 IU versus 1000 IU daily oral vitamin D3 supplementation in the recovery of symptoms and other clinical parameters among mild to moderate COVID-19 patients with sub-optimal vitamin D status. Study

Design and Setting: A total of 69 reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive adults who were hospitalized for mild to moderate COVID-19 disease were allocated to receive once daily for 2 weeks either 5000 IU oral vitamin D3 (n = 36, 21 males; 15 females) or 1000 IU oral vitamin D3 (standard control) (n = 33, 13 males; 20 females). Anthropometrics were measured and blood samples were taken pre- and post-supplementation. Fasting blood glucose, lipids, serum 25(OH)D, and inflammatory markers were measured. COVID-19 symptoms were noted on admission and monitored until full recovery.

Results: Vitamin D supplementation for 2 weeks caused a significant increase in serum 25(OH)D levels in the 5000 IU group only (adjusted p = 0.003). Within-group comparisons also showed a significant decrease in BMI and IL-6 levels overtime in both groups (p-values < 0.05) but was not clinically significant in between-group comparisons. Kaplan–Meier survival analysis revealed that the 5000 IU group had a significantly shorter time to recovery (days) than the 1000 IU group in resolving cough, even after adjusting for age, sex, baseline BMI, and D-dimer (6.2 ± 0.8 versus 9.1 ± 0.8; p = 0.039), and ageusia (loss of taste) (11.4 ± 1.0 versus 16.9 ± 1.7; p = 0.035).

Conclusion: A 5000 IU daily oral vitamin D3 supplementation for 2 weeks reduces the time to recovery for cough and gustatory sensory loss among patients with sub-optimal vitamin D status and mild to moderate COVID-19 symptoms. The use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19 patients with suboptimal vitamin D status, even for a short duration, is recommended.

Created by admin. Last Modification: Saturday July 24, 2021 02:21:41 GMT-0000 by admin. (Version 10)

Attached files

ID Name Comment Uploaded Size Downloads
15910 5,000 IU somewhat faster.pdf admin 14 Jul, 2021 18:27 1.40 Mb 234
15909 5,000 IU somewhat faster.jpg admin 14 Jul, 2021 18:27 56.73 Kb 421
See any problem with this page? Report it (WORKS NOV 2021)